Bounce Biomedical Limited
06606448
Some Concerns
- Negative net worth (-10)
- Going concern doubt noted in accounts (-10)
Details
Compliance
Last accounts
28/02/2025
small
Next accounts due
30/11/2026
Confirmation statement
Last: 30/05/2025
Due 13/06/2026
Industry
Officers
director · Since 30/05/2008
CHIEF EXECUTIVE OFFICER
BRITISH · ENGLAND · Age 52
director · Since 03/12/2013
ORTHOPAEDIC SURGEON
GERMAN,SWISS · SWITZERLAND · Age 64
director · Since 16/07/2014
COMPANY DIRECTOR
BRITISH · UNITED KINGDOM · Age 65
Also on 13 other boards
director · Since 02/03/2016
SCIENTIST
GERMAN · ENGLAND · Age 77
director · Since 06/07/2020
MEDICAL DEVICE CONSULTANT
BRITISH · UNITED KINGDOM · Age 70
Also on 1 other board
director · Since 17/10/2022
CHIEF EXECUTIVE OFFICER
AMERICAN · UNITED STATES · Age 60
Also on 1 other board
Persons with Significant Control
Orthox Holdings Limited
66, Innovation Drive, Abingdon, OX14 4RQ
Reg: 09315389 · Companies House · Limited By Shares
Notified 06/04/2016
CompanyRankvs 1311+ SIC 72110 peers45
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Going concern doubt: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Going Concern Doubt
the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006 . The auditor's report is unqualified and includes the following: Conclusions relating to going concern We draw your attention to Note 1.2 in the financial statements, which indicates that due to adverse results on recent clinical trials, the company's ability to continue as a going concern
Key FinancialsYear ending 28/02/2025
Net Worth
-£1.9M
Balance sheet strength
Cash
£350k
Cash in the bank
Net Current Assets
£530k
Working capital
Current Assets
£2.0M
Current Liabilities
£1.4M
Fixed Assets
£416k
Debtors
£123k
Balance Sheet
EstimatesDerived
| Year | Current Ratio |
|---|---|
| 2025 | 1.37 |
Derived from filed accounts. Not audited figures.